Evidence map›Paper›PMID 28229223›Full record

ArticleJournal of neural transmission (Vienna, Austria : 1996)2017

Levodopa/carbidopa intestinal gel (LCIG) infusion as mono- or combination therapy.

Carsten Buhmann, R Hilker, P Lingor, C Schrader, J Schwarz, M Wolz, H Reichmann

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of neural transmission (Vienna, Austria : 1996), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 11 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Concomitant Medication Usage with Levodopa-Carbidopa Intestinal Gel: Results from the COSMOS Study.Movement disorders : official journal of the Movement Disorder Society · 2021
    Observational
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Carsten BuhmannDepartment of Neurology, University Medical Center Hamburg-Eppendorf, Martinistrasse 52, 20246, Hamburg, Germany. buhmann@uke.uni-hamburg.de.ORCID 0000-0001-8540-3789
R HilkerDepartment of Neurology, Klinikum Vest, Dorstener Strasse 151, 45657, Recklinghausen, Germany.
P LingorDepartment of Neurology, University Medicine Göttingen, Robert-Koch-Strasse 40, 37075, Göttingen, Germany.
C SchraderDepartment of Neurology and Clinical Neurophysiology, Hannover Medical School, Carl-Neuberg-Strasse 1, 30625, Hannover, Germany.
J SchwarzGeriatric Hospital Haag, Krankenhausstrasse 4, 83527, Haag, Germany.
M WolzDepartment of Neurology, Elblandklinikum Meissen, Nassauweg 7, 01662, Meissen, Germany.
H ReichmannDepartment of Neurology, University Hospital Dresden, Technische Universität Dresden, Fetscherstrasse 74, 01307, Dresden, Germany.
Klinikum Vest · DEMedizinische Hochschule Hannover · DETechnische Universität Dresden · DEUniversität Hamburg · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Levodopa/carbidopa intestinal gel (LCIG) infusion is an effective escalating therapy in patients with Parkinson disease (PD) suffering from motor fluctuations and dyskinesia. Levodopa/carbidopa given continuously as infusion provides an optimized application of the most effective and best tolerable antiparkinsonian drug. It has been proven to have a superior motor effect compared with oral levodopa and to improve also non-motor symptoms. However, invasiveness, discomfort resulting from carrying an external device, and side effects associated with the way of administration limit its application in PD patients. At present, there are no guidelines that delineate to which patients LCIG should be offered as monotherapy, in combination with oral and/or transdermal medication, or as additional therapy to deep brain stimulation (DBS). Based on clinical studies, we propose an expert consensus for neurologists addressing the question when LCIG therapy should be recommended and in which cases LCIG infusion is suggested in combination with other antiparkinsonian drugs and/or DBS. We describe how LCIG should be initiated and what we consider necessary for clinical follow-up. We suggest an algorithm facilitating decision-making with respect to the currently available invasive PD therapies, namely infusion with subcutaneous apomorphine, LCIG, and DBS.

Indexed as

AlgorithmsAntiparkinson AgentsCarbidopaCombined Modality TherapyDecision Support Systems, ClinicalDrug CombinationsDrug Therapy, CombinationHumansInfusion PumpsLevodopaParkinson DiseaseAntiparkinson AgentsCarbidopacarbidopa, levodopa drug combinationDrug CombinationsLevodopaCombination therapyLevodopa/carbidopa infusionMonotherapyParkinson disease

Identifiers

PMID28229223
OpenAlexW2589460285

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.